Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Inflammatory bowel disease management during the COVID-19 outbreak : The 10 do's and don'ts from the ECCO-COVID Taskforce

© The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Our knowledge on COVID-19 is changing and evolving rapidly, with novel insights and recommendations, almost on a daily basis. It behooves the medical community to provide updated information on a regular basis, on best practice to facilitate optimal care of infected patients and appropriate advice for the general population. This is particularly important in the case of patients with chronic conditions, such as Inflammatory Bowel Disease (IBD). In this paper, we compiled the existing evidence on the impact of COVID-19 in IBD patients and provide guidance and on the most appropriate care to adopt during the pandemic. Our review highlighted that IBD, per se, is not a risk factor for COVID-19. However, all IBD patients with symptoms should be tested for SARS-CoV-2 and the procedures for disease management shall be carefully adapted: i) in SARS-CoV-2 positive IBD patients, medical treatments should be re-evaluated (with particular focus on corticosteroids) always with the purpose of treating active disease and maintaining remission; ii) non-urgent surgeries and endoscopic procedures should be postponed for all patients; iii) online consultancy should be implemented; and iv) hospitalization and surgery should be limited to life threatening situations

Year of Publication: 2020
Contained in: Journal of Crohn's & colitis (29.07.2020)
All journal articles: Search for all articles in this journal
Language: English
Contributors: Magro, F | Author
Rahier, J-F
Abeu, C
MacMahon, E
Hart, A
van der Woude, C J
Gordon, H
Adamina, M
Viget, N
Vavricka, S
Kucharzik, T
Leone, S
Siegmund, B
Danese, S
Peyrin-Biroulet, L
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: Journal Article
ISSN: 1876-4479
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Revised 29.07.2020
published: Print-Electronic
Citation Status Publisher
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PMID:
    32722754
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1093/ecco-jcc/jjaa160
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 03035nma a2200529 c 4500
001 NLM313909873
003 DE-601
005 20200729215335.0
007 cr uuu---uuuuu
008 200729s2020 000 0 eng d
024 7 |a 10.1093/ecco-jcc/jjaa160  |2 doi 
028 5 2 |a pubmed20n1284.xml 
035 |a jjaa160 
035 |a (DE-599)NLM32722754 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Magro, F 
245 1 0 |a Inflammatory bowel disease management during the COVID-19 outbreak  |h Elektronische Ressource  |b The 10 do's and don'ts from the ECCO-COVID Taskforce 
300 |a Online-Ressource 
500 |a Date Revised 29.07.2020 
500 |a published: Print-Electronic 
500 |a Citation Status Publisher 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a © The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com. 
520 |a Our knowledge on COVID-19 is changing and evolving rapidly, with novel insights and recommendations, almost on a daily basis. It behooves the medical community to provide updated information on a regular basis, on best practice to facilitate optimal care of infected patients and appropriate advice for the general population. This is particularly important in the case of patients with chronic conditions, such as Inflammatory Bowel Disease (IBD). In this paper, we compiled the existing evidence on the impact of COVID-19 in IBD patients and provide guidance and on the most appropriate care to adopt during the pandemic. Our review highlighted that IBD, per se, is not a risk factor for COVID-19. However, all IBD patients with symptoms should be tested for SARS-CoV-2 and the procedures for disease management shall be carefully adapted: i) in SARS-CoV-2 positive IBD patients, medical treatments should be re-evaluated (with particular focus on corticosteroids) always with the purpose of treating active disease and maintaining remission; ii) non-urgent surgeries and endoscopic procedures should be postponed for all patients; iii) online consultancy should be implemented; and iv) hospitalization and surgery should be limited to life threatening situations 
611 2 7 |a Journal Article  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 |5 DE-601 
700 1 |a Rahier, J-F 
700 1 |a Abeu, C 
700 1 |a MacMahon, E 
700 1 |a Hart, A 
700 1 |a van der Woude, C J 
700 1 |a Gordon, H 
700 1 |a Adamina, M 
700 1 |a Viget, N 
700 1 |a Vavricka, S 
700 1 |a Kucharzik, T 
700 1 |a Leone, S 
700 1 |a Siegmund, B 
700 1 |a Danese, S 
700 1 |a Peyrin-Biroulet, L 
773 0 8 |i in  |t Journal of Crohn's & colitis  |g  (29.07.2020)  |w (DE-601)NLM204029481  |x 1876-4479 
856 4 1 |u http://dx.doi.org/10.1093/ecco-jcc/jjaa160  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |j 2020  |b 29  |c 07